FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221036217> ?p ?o ?g. }

• W4221036217 abstract "Clinical endpoints for upcoming therapeutic trials in frontotemporal dementia (FTD) are increasingly urgent. Cognitive composite scores are often used as endpoints but are lacking in genetic FTD. We aimed to create cognitive composite scores for genetic frontotemporal dementia (FTD) as well as recommendations for recruitment and duration in clinical trial design.A standardized neuropsychological test battery covering six cognitive domains was completed by 69 C9orf72, 41 GRN, and 28 MAPT mutation carriers with CDR® plus NACC-FTLD ≥ 0.5 and 275 controls. Logistic regression was used to identify the combination of tests that distinguished best between each mutation carrier group and controls. The composite scores were calculated from the weighted averages of test scores in the models based on the regression coefficients. Sample size estimates were calculated for individual cognitive tests and composites in a theoretical trial aimed at preventing progression from a prodromal stage (CDR® plus NACC-FTLD 0.5) to a fully symptomatic stage (CDR® plus NACC-FTLD ≥ 1). Time-to-event analysis was performed to determine how quickly mutation carriers progressed from CDR® plus NACC-FTLD = 0.5 to ≥ 1 (and therefore how long a trial would need to be).The results from the logistic regression analyses resulted in different composite scores for each mutation carrier group (i.e. C9orf72, GRN, and MAPT). The estimated sample size to detect a treatment effect was lower for composite scores than for most individual tests. A Kaplan-Meier curve showed that after 3 years, ~ 50% of individuals had converted from CDR® plus NACC-FTLD 0.5 to ≥ 1, which means that the estimated effect size needs to be halved in sample size calculations as only half of the mutation carriers would be expected to progress from CDR® plus NACC FTLD 0.5 to ≥ 1 without treatment over that time period.We created gene-specific cognitive composite scores for C9orf72, GRN, and MAPT mutation carriers, which resulted in substantially lower estimated sample sizes to detect a treatment effect than the individual cognitive tests. The GENFI-Cog composites have potential as cognitive endpoints for upcoming clinical trials. The results from this study provide recommendations for estimating sample size and trial duration." @default.
• W4221036217 created "2022-04-03" @default.
• W4221036217 creator A5006096323 @default.
• W4221036217 creator A5012540754 @default.
• W4221036217 creator A5022217754 @default.
• W4221036217 creator A5026422297 @default.
• W4221036217 creator A5028560179 @default.
• W4221036217 creator A5030513319 @default.
• W4221036217 creator A5033024564 @default.
• W4221036217 creator A5036742639 @default.
• W4221036217 creator A5039110327 @default.
• W4221036217 creator A5040948544 @default.
• W4221036217 creator A5042241854 @default.
• W4221036217 creator A5047159861 @default.
• W4221036217 creator A5049091731 @default.
• W4221036217 creator A5049970675 @default.
• W4221036217 creator A5051167066 @default.
• W4221036217 creator A5052325805 @default.
• W4221036217 creator A5055524428 @default.
• W4221036217 creator A5059183048 @default.
• W4221036217 creator A5059258200 @default.
• W4221036217 creator A5060131002 @default.
• W4221036217 creator A5060633478 @default.
• W4221036217 creator A5068026007 @default.
• W4221036217 creator A5068882196 @default.
• W4221036217 creator A5071308068 @default.
• W4221036217 creator A5071341444 @default.
• W4221036217 creator A5072242679 @default.
• W4221036217 creator A5073371346 @default.
• W4221036217 creator A5081436063 @default.
• W4221036217 creator A5083470216 @default.
• W4221036217 creator A5084033552 @default.
• W4221036217 creator A5084389843 @default.
• W4221036217 creator A5085497748 @default.
• W4221036217 creator A5086774103 @default.
• W4221036217 creator A5086819795 @default.
• W4221036217 creator A5088826332 @default.
• W4221036217 creator A5089813112 @default.
• W4221036217 creator A5090580473 @default.
• W4221036217 date "2022-01-19" @default.
• W4221036217 modified "2023-10-18" @default.
• W4221036217 title "Cognitive composites for genetic frontotemporal dementia: GENFI-Cog" @default.
• W4221036217 cites W1499568698 @default.
• W4221036217 cites W1508702903 @default.
• W4221036217 cites W1847168837 @default.
• W4221036217 cites W1912893579 @default.
• W4221036217 cites W1953027527 @default.
• W4221036217 cites W1965616054 @default.
• W4221036217 cites W1991714215 @default.
• W4221036217 cites W2000540030 @default.
• W4221036217 cites W2001843555 @default.
• W4221036217 cites W2008854521 @default.
• W4221036217 cites W2011937112 @default.
• W4221036217 cites W2011963094 @default.
• W4221036217 cites W2037166708 @default.
• W4221036217 cites W2058161128 @default.
• W4221036217 cites W2058223996 @default.
• W4221036217 cites W2102932082 @default.
• W4221036217 cites W2106786486 @default.
• W4221036217 cites W2128030851 @default.
• W4221036217 cites W2130159618 @default.
• W4221036217 cites W2138190873 @default.
• W4221036217 cites W2146088791 @default.
• W4221036217 cites W2148080316 @default.
• W4221036217 cites W2150753346 @default.
• W4221036217 cites W2152481146 @default.
• W4221036217 cites W2161938104 @default.
• W4221036217 cites W2166770399 @default.
• W4221036217 cites W2167311298 @default.
• W4221036217 cites W2167500413 @default.
• W4221036217 cites W2334692654 @default.
• W4221036217 cites W2443339653 @default.
• W4221036217 cites W2470439561 @default.
• W4221036217 cites W2619097621 @default.
• W4221036217 cites W2624766892 @default.
• W4221036217 cites W2625796101 @default.
• W4221036217 cites W2750650624 @default.
• W4221036217 cites W2773789615 @default.
• W4221036217 cites W2795986531 @default.
• W4221036217 cites W2898356427 @default.
• W4221036217 cites W2899111132 @default.
• W4221036217 cites W2901056969 @default.
• W4221036217 cites W2904608802 @default.
• W4221036217 cites W2944460071 @default.
• W4221036217 cites W2980420390 @default.
• W4221036217 cites W2999672061 @default.
• W4221036217 cites W3005464778 @default.
• W4221036217 cites W3005780323 @default.
• W4221036217 cites W3012639103 @default.
• W4221036217 cites W3036059671 @default.
• W4221036217 cites W3089282125 @default.
• W4221036217 cites W3161543087 @default.
• W4221036217 doi "https://doi.org/10.1186/s13195-022-00958-0" @default.
• W4221036217 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35045872" @default.
• W4221036217 hasPublicationYear "2022" @default.
• W4221036217 type Work @default.
• W4221036217 citedByCount "3" @default.
• W4221036217 countsByYear W42210362172022 @default.
• W4221036217 countsByYear W42210362172023 @default.
• W4221036217 crossrefType "journal-article" @default.

• next